{"id":"294359117093-66","name":"UCB","registrationDate":"2015-04-24T10:35:14.049+01:00","category":2,"subCategory":3,"legal":"Public Limited Company","web":"http://www.ucb.com","country":"Belgium","headAddress":"Allée de la Recherche 60","headCity":"Brussels","headPostCode":"1070","headPhone":"(32)25 59 99 99","boss":"Jean-Christophe Tellier","bossTitle":"Mr","bossPosition":"CEO","membersCount":2,"membersFTE":"0.75","membership":"EFPIA = European Federation of Pharmaceutical Industries and Associations&#xd;\n(http://efpia.eu/)&#xd;\n&#xd;\nEBE = European Biopharmaceuticals Entreprises (http://www.ebe-biopharma.eu/)","memberOrga":"","goal":"UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of € 4.2 billion in 2016. UCB is listed on Euronext Brussels (symbol: UCB).","acronym":"","interests":"Competition, Consumer Affairs, Economic and Financial Affairs, Employment and Social Affairs, Information Society, Internal Market, Public Health, Research and Technology","euInitiatives":"Engage governments and policymakers worldwide on issues important to UCB to:&#xd;<br />• Ensure patients have access to medicines they need&#xd;<br />• Provide coverage and reimbursement that reward innovation&#xd;<br />• Introduce sound, science-based regulation&#xd;<br />• Enable biotechnology research and development (R&amp;D)","lastUp":"2017-04-20T11:33:25.576+01:00","customers":"","costAbsolu":"","costRange":"200000-299999","turnoverAbsolu":0,"turnoverRange":""}